From January 1, 2023 to March 31, 2023, the company has repurchased 87,694 shares, representing 1.06% for $0.3 million. With this, the company has completed the repurchase of 225,220 shares, representing 2.7% for $0.96 million under the buyback announced on August 16, 2022.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.339 USD | -2.13% | -2.95% | -26.45% |
04/06 | Lumos Pharma, Inc. Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024 | CI |
15/05 | Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.45% | 1.94Cr | |
+37.90% | 5.37TCr | |
+33.53% | 3.89TCr | |
-8.48% | 3.88TCr | |
-10.77% | 2.73TCr | |
+11.22% | 2.59TCr | |
-15.62% | 2.03TCr | |
+32.35% | 1.28TCr | |
+28.21% | 1.22TCr | |
-2.57% | 1.2TCr |
- Stock Market
- Equities
- LUMO Stock
- News Lumos Pharma, Inc.
- Tranche Update on Lumos Pharma, Inc.'s Equity Buyback Plan announced on August 16, 2022.